Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study, published in "Más Dermatol," explores how multiple factors contribute to hair loss, such as genetics, hormones, oxidative stress, microinflammation, and emotional stress, and highlights interventions targeting these causes to improve hair regrowth and quality of life.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

This study found that mutant glucocorticoid receptors have defective transcriptional activity and dynamic motility issues in the nucleus, likely due to impaired interactions with nuclear molecules necessary for gene activation.

Raltegravir may cause hair loss in some patients.

This study found that miR-432 inhibits KRT83 expression, revealing potential molecular mechanisms for the formation of curly fleece in Tan sheep and suggesting implications for understanding curly hair formation in humans.

This study found that inhibiting the Mitochondrial Pyruvate Carrier in human scalp hair follicles caused metabolic stress that halted cell proliferation and disrupted key signaling pathways, with these effects partially reversed by an integrated stress response inhibitor.

Skin conditions can signal heart issues, highlighting the need for integrated care.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

In this study, finasteride was found not to be associated with changes in sleep spindle activity or morphology in men undergoing sleep studies.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

This study found that inhibiting the Mitochondrial Pyruvate Carrier in human hair follicles ex vivo activated the integrated stress response, affecting cell proliferation and metabolism.

This study validated a protocol for inducing surface ectoderm differentiation from human induced pluripotent stem cells and highlighted the role of TGFβ signaling pathways in this process.

In this study, patients with alopecia areata indicated a preference for shared decision-making (SDM) with their dermatologists, and those who engaged in SDM reported less decisional regret about their treatment choices.

JAK inhibitors may reduce depression risk in alopecia areata patients.

This study examines the genetic underpinnings of chronic dermatological conditions like acne, androgenetic alopecia, and alopecia areata, concluding that a deep understanding of these mechanisms can advance patient-specific treatments and inform cosmetic practices related to skin and hair health.

This study analyzed the economic burden of alopecia areata in Saudi Arabia, finding significant costs driven by productivity loss and drug expenses, with severe cases incurring higher expenses, emphasizing the need for better treatment protocols and access to therapies.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

This study found that FZD2 is crucial for hair follicle formation and postnatal growth in mice and has a novel role in regulating early epidermal development, including stratification and cornification.

This study found that recombinant human ADM2 treatment inhibited cell proliferation and induced apoptosis in human hair follicles, contrasting with the previously documented pro-proliferative and anti-apoptotic functions of ADM2.

This review analyzes recent research trends on alopecia and reports no new results, highlighting findings in Western medicine and TCM related to combination therapies, patients' characteristics, and treatment approaches.

This study identified ectodin as a novel BMP inhibitor that modulates BMP signaling in ectodermal development by interacting with SHH and FGF pathways.

This study suggests that MPZL3, a mitochondrially localized protein, may play an integral role in regulating hair follicle cycles, with potential therapeutic implications for hair growth disorders if findings translate to humans.